Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN Study

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 1028-1035

  Francis, C W ^a   Kessler, C M ^b   Goldhaber, S Z ^c   Kovacs, M J ^d   Monreal, M ^e   Huisman, M V ^f   Bergqvist, D ^g   Turpie, A G ^h   Ortel, T L ⁱ   Spyropoulos, A C ^a   Pabinger, I ^j   Kakkar, A K ^k  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

Cancer; Dalteparin; Deep vein thrombosis; Low molecular weight heparin; Pulmonary embolism; Venous thromboembolism

Indexed keywords

DALTEPARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CAUSE OF DEATH; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOPERICARDIUM; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODERATE RENAL IMPAIRMENT; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; RISK FACTOR; SEVERE RENAL IMPAIRMENT; SPINAL HEMATOMA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; BLEEDING; BLOOD; CANADA; CHEMICALLY INDUCED; COMPLICATION; DRUG ADMINISTRATION; EUROPE; METABOLISM; NEOPLASMS; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTICOAGULANTS; CANADA; DALTEPARIN; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84930182283     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12923     Document Type: Article

References (15)

1. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 23(Suppl 1): I17-21.
2. Lee A, Peterson E. Treatment of cancer-associated thrombosis. Blood 2013; 14: 2310-7.
3. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 10: 1712-23.
4. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchori A, Sabbion P, Prins MH, Norenta F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
5. Gussoni G, Frasson S, La Regina M, DiMicco P, Monreal M, RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 1: 24-30.
6. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 3: 632-4.
7. Sorenson HT, Mellamkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 25: 1846-50.
8. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
9. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G, LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-72.
10. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, LeMaignan C, Extra JM, Cotty P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
11. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Executive summary: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 2 (Suppl): 7S-47S.
12. National Comprehensive Cancer Network. NCCN Guidelines in oncology: venous thromboembolic disease. http://www.nccn.org/professionals/physucuan_gls/pdf/vte.pdf; Version 2.2013. Accessed 15 October 2014.
13. Lyman GH, Bonike K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 17: 2189-204.
14. Schulman S, Angeras U, Bergqvist D, Erikson B, Lassen MR, Fisher W, on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-4.
15. Akl EA, Labedi N, Barba M, Terrenato I, Sperati F, Muti P, Schünemann H. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (CD006650).